DOP2021000236A - Formas de sales cristalinas de un inhibidor de cinasas - Google Patents

Formas de sales cristalinas de un inhibidor de cinasas

Info

Publication number
DOP2021000236A
DOP2021000236A DO2021000236A DO2021000236A DOP2021000236A DO P2021000236 A DOP2021000236 A DO P2021000236A DO 2021000236 A DO2021000236 A DO 2021000236A DO 2021000236 A DO2021000236 A DO 2021000236A DO P2021000236 A DOP2021000236 A DO P2021000236A
Authority
DO
Dominican Republic
Prior art keywords
salt forms
crystalline salt
kinase inhibitor
relates
disorder
Prior art date
Application number
DO2021000236A
Other languages
English (en)
Inventor
Demorin Frenel
Shah Khalid
Shakya Sagar
Wong Peter
S Johnson Courtney
Janelle Bevill Melanie
D Parent Stephan
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of DOP2021000236A publication Critical patent/DOP2021000236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención está relacionada con las formas cristalinas de sales del Compuesto 1. La invención también está relacionada con composiciones farmacéuticas que comprenden las sales cristalinas sólidas del Compuesto 1. La invención está relacionada además con métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos en parte por la modulación de la actividad in vivo de una proteína cinasa.
DO2021000236A 2019-06-03 2021-11-17 Formas de sales cristalinas de un inhibidor de cinasas DOP2021000236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
DOP2021000236A true DOP2021000236A (es) 2022-04-18

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000236A DOP2021000236A (es) 2019-06-03 2021-11-17 Formas de sales cristalinas de un inhibidor de cinasas

Country Status (18)

Country Link
US (1) US20230052703A1 (es)
EP (1) EP3976587A1 (es)
JP (1) JP2022535072A (es)
KR (1) KR20220016117A (es)
CN (1) CN113939503B (es)
AU (1) AU2019449809A1 (es)
BR (1) BR112021024300A2 (es)
CA (1) CA3139148A1 (es)
CL (1) CL2021003205A1 (es)
CO (1) CO2021017343A2 (es)
CR (1) CR20210616A (es)
DO (1) DOP2021000236A (es)
IL (1) IL288484A (es)
MA (1) MA56001A (es)
MX (1) MX2021014773A (es)
PE (1) PE20220962A1 (es)
SG (1) SG11202111978VA (es)
WO (1) WO2020247019A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200358A (es) * 2018-01-26 2021-02-22 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
CN113329790A (zh) * 2018-12-13 2021-08-31 埃克塞里艾克西斯公司 激酶抑制剂的结晶形式和盐形式
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2213661T1 (sl) * 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
JP5039027B2 (ja) 2005-04-15 2012-10-03 ネオジェニックス オンコロジー， インコーポレイテッド 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
DK3630726T3 (da) * 2017-05-26 2022-03-07 Exelixis Inc Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse
CR20200358A (es) * 2018-01-26 2021-02-22 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
US20230052703A1 (en) 2023-02-16
JP2022535072A (ja) 2022-08-04
IL288484A (en) 2022-01-01
MA56001A (fr) 2022-04-06
CA3139148A1 (en) 2020-12-10
CN113939503B (zh) 2024-05-07
CR20210616A (es) 2022-03-22
PE20220962A1 (es) 2022-06-10
CL2021003205A1 (es) 2022-09-30
SG11202111978VA (en) 2021-11-29
CO2021017343A2 (es) 2022-01-17
CN113939503A (zh) 2022-01-14
MX2021014773A (es) 2022-01-18
WO2020247019A1 (en) 2020-12-10
KR20220016117A (ko) 2022-02-08
BR112021024300A2 (pt) 2022-01-11
EP3976587A1 (en) 2022-04-06
AU2019449809A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CL2021003205A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CL2020003101A1 (es) Sales de sepiapterina farmacéuticamente aceptables.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
NI202100018A (es) Moduladores de la expresión de pnpla3
CL2023001268A1 (es) Composiciones farmacéuticas de un inhibidor de cinasa
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CO2021011042A2 (es) Sales de sulcardina
CU20220024A7 (es) Compuestos aromáticos bicíclicos derivatizados por ácido fenilacético y bencilamina, útiles en el tratamiento de trastornos inmunológicos, enfermedades del sistema nervioso central, neurodegenerativas, renales y cardiovasculares
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
ECSP22001370A (es) Inhibidores de prmt5
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
PE20200749A1 (es) Moduladores de la expresion de enac
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
EA202191653A1 (ru) Кристаллические формы и солевые формы ингибитора киназы